Phal-501
COPD and Chronic Fatigue Syndrome (Proof-of-Concept)
Pre-clinicalActive
Key Facts
Indication
COPD and Chronic Fatigue Syndrome (Proof-of-Concept)
Phase
Pre-clinical
Status
Active
Company
About PharmaLundensis
PharmaLundensis is a preclinical-stage biotech developing Phal-501, a novel oral chelator for heavy metal detoxification. The company is seeking $6 million in funding to advance into GMP production and proof-of-concept clinical studies in COPD and chronic fatigue syndrome. Founded and led by physician-scientist Staffan Skogvall, the company is publicly traded in Sweden but remains pre-revenue, with its technology protected by a recently published patent application. Key risks include early-stage development, clinical validation, and securing necessary financing.
View full company profile